Empagliflozin after Acute Myocardial Infarction | NEJM

SGLT2 inhibitors improve cardiovascular outcomes in high-risk patients with diabetes, chronic kidney disease, or heart failure, but their effects after acute myocardial infarction are unknown.
Research findings are summarized in a new Quick Take video.
To see the full article, follow this link: nej.md/4cEb6EB
#cardiology #clinicalmedicine #clinicaltrials #nejm

[@mariobonilla4960]

Thank you, NEJM.

[@adithyavikram7]

There are many limitations in this study

[@AmericanFUBAR33]

I always thought SGLT 2 are overhyped.

[@adithyavikram7]

Respected professor when usually you start Sglt2 inhibitors in your practice in a patient with acute mi , like immediately or after 24 hours or after 72 hours or during discharge, when you want to prefer the Sglt2 inhibitor professor, thank you in anticipation.